Abbvie Inc.

Abbvie Deutschland Gmbh and Co Kg

Abbott Laboratories Corporation

Abbott Gmbh & Co Kg

Zoetis Belgium S.a

Calico Life Sciences LLC

Abbvie Bahamas Limited

Charles W Hutchins

Wilhelm Amberg

Udo Lange

Michael Ochse

Wilfried Hornberger

Andreas Kling

Frauke Pohlki

Berthold Behl

David A DeGoey

Warren M Kati

Pamela L Donner

Steven Armen Boyd

Mario Mezler

John T Randolph

Allan C Krueger

Sachin V Patel

Tammie K Jinkerson

Christopher E Motter

Mark A Matulenko

Ryan G Keddy

Lissa T Nelson

Andrew Stewart Tasker

Martin Winn

Bryan K Sorensen

Thomas W Von Geldern

Hwan-soo Jae

Jeffrey A Kester

Katja Jantos

John K Pratt

Wolfgang Wernet

Rolf Wagner

Todd Warren Rockway

Dachun Liu

David A Betebenner

Douglas K Hutchinson

Clarence J Maring

Charles A Flentge

Kevin R Woller

Michael D Tufano

Yi Gao

Astrid Netz

Kathy A Sarris

Seble H Wagaw

Wenke Li

Gang Liu

Helmut Mack

Achim Moeller

Steven J Wittenberger

Steven A King

Ying Wang

Bruce G Szczepankiewicz

Hongyu H Zhao

Kenneth J Henry

William A Carroll

Anil Vasudevan

Yanbin Lao

Jason T Brewer

Wilfried Martin Braje

Sean Colm Turner

Michael J Dart

Lawrence A Black

Jennifer M Frost

Ravi Chari

Lei Shi

Yunsong Tong

Marina Pliushchev

Ramzi Farah Sweis

Xiangdong Xu

Mary Leddy

Qingwei I Zhang

Liliane Unger

Stevan Wakefield Djuric

Thorsten K Oost

Chung-Ming Hsieh

Hervé Geneste

Anthony K Fung

Tami J Pilot-Matias

Herve Geneste

William R Baker

Herman H Stein

Justin D Dietrich

Marcel Van Gaalen

Loic Laplanche

Wilfried Lubisch

Xiaohong Song

Saul H Rosenberg

Kenton L Longenecker

John Peter Fischer

Tongmei Li

Keith W Woods

Gui-Dong Zhu

Vincent L Giranda

Jieyi Wang

Garrick Kenneth Packard

Qun Li

Jianchun Gong

Sheela A Thomas

Virajkumar B Gandhi

Edward B Reilly

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

Modulators of the integrated stress pathway

The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.

Fused heterocyclic compounds as S1P modulators

The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).

Prolactin receptor binding proteins and uses thereof

The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.

Caninized anti-NGF antibodies and their use

Anti-NGF antibodies and their use

Compounds effective in inhibiting replication of Hepatitis C virus ('HCV') are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

The present invention relates to novel substituted oxindole derivatives of formula (I) wherein the variables are as defined in the claims and description; to pharmaceutical compositions comprising them, and to their use for the treatment of vasopressin-related disorders. 

Oxindole derivatives carrying an amine-substituted piperidyl-acetidinyl substituent and use thereof for treating vasopressine-related diseases

The present invention relates to novel substituted oxindole derivatives of formula (I) wherein the variables are as defined in the claims and description; to pharmaceutical compositions comprising them, and to their use for treatment of vasopressin-related disorders. 

Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases

The present invention relates to pyrrolidine derivatives of the formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.

Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy

The present invention relates to aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, and the use of such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives for therapeutic purposes. The aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives are GlyT1 inhibitors.

Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy

The present invention relates to aminotetraline and aminoindane derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline and aminoindane derivatives, and the use of such aminotetraline and aminoindane derivatives for therapeutic purposes. The aminotetraline and aminoindane derivatives are GlyT1 inhibitors.

Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy

Growing community of inventors

Green Oaks, IL, United States of America

Charles W Hutchins